Over the past few years the approval of maintenance therapies in gynecologic cancers have increased. The recent ASCO Annual meeting held a full session titled Wanna Get Away - Maintenance Treatments and Chemo Holidays in Gyn Cancers which included maintenance therapies for women diagnosed with gynecologic cancers. Women with High Grade Serous Ovarian Cancer (HGSOC) may choose to use Bevacizumab or PARP inhibitors as maintenance therapies. Women with Low Grade Serous Ovarian Cancer (LGSOC) may be offered hormonal treatment. Research into using maintenance therapies with endometrial and other gyn cancers continues.
On Wednesday, July 10, 2019 at 9pm ET (8pmCT, 6pmPT) join the #gyncsm community as we discuss the use of maintenance therapies for gyn cancers. Learn what treatments are available for your gyn cancer and what questions you should ask when considering maintenance therapy.
Chat topic Questions:
T1: What are maintenance therapies and why are they used?
Chat topic Questions:
T1: What are maintenance therapies and why are they used?
T2A: What evidence was there to approve Avastin (Bevacizumab) for maintenance?
T2B: How long is Bev given? What side effects may women experience with maintenance Bev? Is Bev limited to women with a BRCA mutation?
T3A: PARP inhibitors were approved for recurrent ovarian cancer and now for maintenance therapy for women with the BRCA mutation. What study results led to the FDA approval?
T3B How long is PARP given during maintenance? What side effects may women experience?
T4: Are maintenance drugs given for other gyn cancers? Cervical, endometrial, etc?
T5: What questions should a patient ask when offered a maintenance therapy?
See you on Wednesday!
Dee
#gyncsm Co-founder
No comments:
Post a Comment